TNF Pharmaceuticals (TNFA) Competitors $3.71 -0.15 (-3.89%) Closing price 04:00 PM EasternExtended Trading$3.70 0.00 (-0.13%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock TNFA vs. KZR, TENX, DARE, MTVA, CVKD, LIXT, LEXX, XCUR, RNTX, and CASIShould you be buying TNF Pharmaceuticals stock or one of its competitors? The main competitors of TNF Pharmaceuticals include Kezar Life Sciences (KZR), Tenax Therapeutics (TENX), Dare Bioscience (DARE), MetaVia (MTVA), Cadrenal Therapeutics (CVKD), Lixte Biotechnology (LIXT), Lexaria Bioscience (LEXX), Exicure (XCUR), Rein Therapeutics (RNTX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. TNF Pharmaceuticals vs. Its Competitors Kezar Life Sciences Tenax Therapeutics Dare Bioscience MetaVia Cadrenal Therapeutics Lixte Biotechnology Lexaria Bioscience Exicure Rein Therapeutics CASI Pharmaceuticals TNF Pharmaceuticals (NASDAQ:TNFA) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Is TNFA or KZR more profitable? Kezar Life Sciences' return on equity of -63.51% beat TNF Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TNF PharmaceuticalsN/A -69.21% -33.98% Kezar Life Sciences N/A -63.51%-52.13% Do analysts recommend TNFA or KZR? Kezar Life Sciences has a consensus target price of $9.00, indicating a potential upside of 135.60%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Kezar Life Sciences is more favorable than TNF Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals and insiders believe in TNFA or KZR? 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer TNFA or KZR? In the previous week, TNF Pharmaceuticals had 2 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for TNF Pharmaceuticals and 0 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.00 beat TNF Pharmaceuticals' score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment TNF Pharmaceuticals Neutral Kezar Life Sciences Positive Which has stronger earnings & valuation, TNFA or KZR? Kezar Life Sciences is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTNF PharmaceuticalsN/AN/A-$23.36M-$231.00-0.02Kezar Life SciencesN/AN/A-$83.74M-$9.69-0.39 Which has more volatility and risk, TNFA or KZR? TNF Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. SummaryKezar Life Sciences beats TNF Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get TNF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNFA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNFA vs. The Competition Export to ExcelMetricTNF PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.86M$2.52B$5.79B$10.49BDividend YieldN/A55.04%5.61%4.57%P/E Ratio-0.0223.26348.8926.87Price / SalesN/A563.62522.55164.30Price / CashN/A27.8326.0131.15Price / Book0.015.3615.536.50Net Income-$23.36M$32.95M$3.29B$271.42M7 Day Performance-7.02%3.96%200.87%3.69%1 Month Performance-40.64%5.27%184.38%8.07%1 Year Performance-97.03%-0.72%325.51%29.65% TNF Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNFATNF Pharmaceuticals0.1704 of 5 stars$3.71-3.9%N/A-96.9%$6.86MN/A-0.026KZRKezar Life Sciences3.7552 of 5 stars$3.84-1.9%$9.00+134.7%-34.1%$28.08MN/A-0.4060Positive NewsGap UpTENXTenax Therapeutics2.5041 of 5 stars$6.12+0.4%$18.00+194.3%+79.6%$28.04MN/A-6.689DAREDare Bioscience2.1104 of 5 stars$2.06+1.5%$10.00+385.4%-35.0%$27.77M$10K-0.9630Positive NewsMTVAMetaVia1.7854 of 5 stars$1.14-24.0%$7.50+557.9%N/A$27.59MN/A0.008Gap DownHigh Trading VolumeCVKDCadrenal Therapeutics3.2393 of 5 stars$13.45+0.6%$32.00+137.9%+13.6%$27.57MN/A-1.514LIXTLixte Biotechnology0.8351 of 5 stars$5.88+3.1%N/A+189.9%$26.80MN/A-4.554LEXXLexaria Bioscience3.2719 of 5 stars$1.35+3.8%$4.00+196.3%-62.0%$26.41M$460K-2.017Positive NewsXCURExicure0.7438 of 5 stars$4.06-0.2%N/A-9.2%$26.16M$500K-1.0750RNTXRein Therapeutics2.423 of 5 stars$1.10-0.9%N/AN/A$25.64MN/A-0.419News CoverageAnalyst ForecastCASICASI Pharmaceuticals3.2887 of 5 stars$2.08-0.5%$4.00+92.3%-72.5%$25.57M$28.54M-0.72180Gap Up Related Companies and Tools Related Companies Kezar Life Sciences Alternatives Tenax Therapeutics Alternatives Dare Bioscience Alternatives MetaVia Alternatives Cadrenal Therapeutics Alternatives Lixte Biotechnology Alternatives Lexaria Bioscience Alternatives Exicure Alternatives Rein Therapeutics Alternatives CASI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNFA) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
